Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25286793 | 1.00 | USP2 (0.47) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL24095376 | 0.90 | HPGD (0.45) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL3940936 | 0.90 | HPGD (0.45) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL24711544 | 0.90 | HPGD (0.45) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL78071 | 0.89 | USP2 (0.55) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL14801055 | 0.89 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2NR1H2 | |
| SCHEMBL31460589 | 0.88 | HPGD (0.48) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL31460689 | 0.88 | HPGD (0.48) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL31603608 | 0.88 | HPGD (0.48) | USP2SMN1; SMN2CYP11B2USP30HPGD | |
| SCHEMBL4210880 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2CYP11B2USP30HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2007097470-A2 | FUSED NITROGEN- COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | WO | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| EP-1538150-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-20070066584-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20050096357-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. | 2005-05-05 | — | — | US | disclosed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | USP2 2528/4885SMN1; SMN2 335/4885CYP11B2 3867/4885 |
| US-20040024059-A1 | Novel pleuromutilin derivatives | PLEC, MLNR, FABP2 | USP2 1067/4885SMN1; SMN2 3080/4885CYP11B2 4780/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | USP2 1293/4885SMN1; SMN2 1067/4885CYP11B2 1873/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | USP2 3733/4885SMN1; SMN2 1436/4885CYP11B2 194/4885 |
| US-20070066584-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | USP2 4557/4885SMN1; SMN2 3627/4885CYP11B2 4/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | USP2 1115/4885SMN1; SMN2 1443/4885CYP11B2 1324/4885 |
| US-20050096357-A1 | Novel pleuromutilin derivatives | FABP2, PLEC, MLNR | USP2 980/4885SMN1; SMN2 3135/4885CYP11B2 4773/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | USP2 3733/4885SMN1; SMN2 1436/4885CYP11B2 194/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | USP2 4143/4885SMN1; SMN2 1509/4885CYP11B2 242/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | USP2 4557/4885SMN1; SMN2 3627/4885CYP11B2 4/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | USP2 2513/4885SMN1; SMN2 382/4885CYP11B2 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.